Elraglusib Plus Chemotherapy Shows Survival Benefit in Pancreatic Cancer

In a randomized phase 2 study in metastatic pancreatic cancer, investigators reported longer survival with chemotherapy plus elraglusib than with chemotherapy alone. One-year survival was 44% in the combination group and 22% with chemotherapy alone, and researchers reported a 38% reduction in the risk of death.

The phase 2 randomized trial enrolled 233 patients with metastatic pancreatic cancer at 60 sites in six countries across North America and Europe. Participants were assigned to chemotherapy alone or to chemotherapy plus elraglusib. Median overall survival was 10.1 months with elraglusib and 7.2 months in the control group. About 13% of the elraglusib arm remained alive at two years, versus none in the control group. The authors said the roughly three-month median gap may partly reflect rapid early progression in some patients.

Investigators described adverse events as generally consistent with chemotherapy, although they were somewhat more common in the elraglusib group. Low white blood cell counts, fatigue, and temporary vision changes were the most frequently reported side effects. The authors characterized the overall safety profile as manageable and noted that the vision changes were reversible.

The study described elraglusib as targeting GSK-3 beta and acting on the tumor microenvironment rather than functioning like traditional chemotherapy. Researchers also reported increased cancer-fighting cells within tumors among patients who received the drug during the trial. Baseline immune-related blood markers at trial entry were associated with longer survival in the elraglusib group. These tumor and blood findings were presented as exploratory signals, not as confirmed mechanism evidence or ready-to-use predictive markers. The biologic observations were reported alongside the clinical outcomes as preliminary findings.

Investigators described the findings as encouraging, while noting that the results will need to be confirmed in phase 3 trials. They said a larger confirmatory phase 3 trial is under consideration as funding and partnership allow. The group also expressed interest in studying elraglusib with other novel therapies in additional combination strategies.

Key Takeaways

• Elraglusib plus chemotherapy was reported to be associated with longer survival than chemotherapy alone in this randomized phase 2 trial of metastatic pancreatic cancer.
• Adverse events were described as broadly aligned with chemotherapy, though somewhat more common with elraglusib, with low white blood cell counts, fatigue, and temporary vision changes among frequently reported events.
• Researchers reported exploratory immune-related signals, and investigators said confirmatory phase 3 evaluation is under consideration.